Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | emeis: Growth in Revenue in First-Half 2024 at €2,772 Million (Up 9.2%) | 245 | Business Wire | Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726471228/en/
emeis (Paris:EMEIS):
Growth in revenue in first-half... ► Artikel lesen | |
Fr | Vallourec Second Quarter 2024 Results | 176 | GlobeNewswire (Europe) | Meudon (France), July 26th, 2024
Vallourec, a world leader in premium tubular solutions, announces today its results for the second quarter 2024. The Board of Directors of Vallourec SA, meeting... ► Artikel lesen | |
Fr | Vallourec: availability of the Interim Financial Report (half-year ended 30 June 2024) | 175 | GlobeNewswire (Europe) | Vallourec: availability of the Interim Financial Report(half-year ended 30 June 2024)
Meudon (France), July 26th 2024 - The Vallourec Interim financial report ended 30 June 2024 has been made available... ► Artikel lesen | |
Fr | Ipsen Pharma: Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases | 160 | GlobeNewswire (Europe) | Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
CHMP positive... ► Artikel lesen | |
Fr | Sopra Steria Group: 2024 Half-Year Financial Report Now Available | 143 | Business Wire | Regulatory News:
Sopra Steria (Paris:SOP) announces today that they have made available to the public and filed with the Autorité des Marchés Financiers (AMF) the half-yearly Financial Report at... ► Artikel lesen | |
Fr | GENFIT S.A.: Positive Opinion from EMA Committee for Ipsen's Iqirvo (elafibranor) in Primary Biliary Cholangitis | 98 | GlobeNewswire (Europe) | Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the... ► Artikel lesen | |
Fr | Amundi: First Half & Second Quarter 2024 results | 70 | GlobeNewswire (Europe) | Amundi: First Half & Second Quarter 2024 results Strong Net income1 growth of +9.4%2 and high net inflows of +€15bn in Q2 Robust growth for net income and revenues Q2 2024: Adjusted net income1... ► Artikel lesen |
Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
---|---|---|---|---|---|---|
ICADE | 20,780 | 4,84 | +23,29 % | |||
M6 METROPOLE TELEVISION | 12,180 | 1,25 | +10,26 % | |||
![]() | SES | 4,940 | 0,50 | +10,12 % | ||
ESSO SAF | 149,40 | 15,00 | +10,04 % | |||
MERCIALYS | 11,280 | 0,99 | +8,78 % | |||
VERALLIA | 26,380 | 2,15 | +8,15 % | |||
![]() | APERAM | 25,160 | 2,00 | +7,95 % | 0,50 | 16.08.2024 |
BENETEAU | 9,220 | 0,73 | +7,92 % | 0,73 | 12.06.2024 | |
COVIVIO | 46,260 | 3,30 | +7,13 % | |||
RUBIS | 28,720 | 1,98 | +6,89 % | 1,98 | 14.06.2024 |
Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
---|---|---|---|---|---|
AEROPORTS DE PARIS SA A0J2WM Tradegate | 121,900 118,30 | -0,50 -0,41 % | 26.07. | ||
ALTEN SA 918312 Frankfurt | 100,300 97,15 | +3,15 +3,24 % | 26.07. | ||
AMUNDI SA A143DP Tradegate | 67,150 65,55 | +0,15 +0,22 % | 26.07. | ||
APERAM SA A1H5UL Tradegate | 25,160 24,940 | +0,160 +0,64 % | 26.07. | ||
ARGAN SA A0MVRB Frankfurt | 76,100 75,80 | +0,30 +0,40 % | 26.07. | ||
ATOS SE 877757 Tradegate | 0,951 1,026 | -0,009 -0,96 % | 26.07. | ||
AYVENS SA A2DSXM Tradegate | 6,255 6,125 | +0,010 +0,16 % | 26.07. | ||
BENETEAU SA 882042 Tradegate | 9,220 9,060 | +0,030 +0,33 % | 26.07. | ||
BIC SA 860804 Tradegate | 57,700 57,40 | -0,20 -0,35 % | 26.07. | ||
BOLLORE SE 875558 Tradegate | 5,675 5,660 | -0,020 -0,35 % | 26.07. |